Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties

Atreyi Dasgupta, Matteo Trucco, Nino Rainusso, Ronald J. Bernardi, Ryan Shuck, Lyazat Kurenbekova, David M. Loeb, Jason T. Yustein

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Ewing sarcoma (EWS) is a highly aggressive and metabolically active malignant tumor. Metabolic activity can broadly be characterized by features of glycolytic activity and oxidative phosphorylation. We have further characterized metabolic features of EWS cells to identify potential therapeutic targets. EWS cells had significantly more glycolytic activity compared to their non-malignant counterparts. Thus, metabolic inhibitors of glycolysis such as 2-deoxy-D-glucose (2DG) and of the mitochondrial respiratory pathway, such as metformin, were evaluated as potential therapeutic agents against a panel of EWS cell lines in vitro. Results indicate that 2DG alone or in combination with metformin was effective at inducing cell death in EWS cell lines. The predominant mechanism of cell death appears to be through stimulating apoptosis leading into necrosis with concomitant activation of AMPK-α. Furthermore, we demonstrate that the use of metabolic modulators can target putative EWS stem cells, both in vitro and in vivo, and potentially overcome chemotherapeutic resistance in EWS. Based on these data, clinical strategies using drugs targeting tumor cell metabolism present a viable therapeutic modality against EWS.

Original languageEnglish (US)
Pages (from-to)77292-77308
Number of pages17
JournalOncotarget
Volume8
Issue number44
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Ewing's Sarcoma
Neoplastic Stem Cells
Growth
Metformin
Deoxyglucose
Cell Death
Cell Line
AMP-Activated Protein Kinases
Oxidative Phosphorylation
Glycolysis
Drug Delivery Systems
Neoplasms
Necrosis
Stem Cells
Therapeutics
Apoptosis

Keywords

  • 2DG
  • Cancer stem cells
  • Ewing sarcoma
  • Metabolism
  • Metformin

ASJC Scopus subject areas

  • Oncology

Cite this

Dasgupta, A., Trucco, M., Rainusso, N., Bernardi, R. J., Shuck, R., Kurenbekova, L., ... Yustein, J. T. (2017). Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties. Oncotarget, 8(44), 77292-77308. https://doi.org/10.18632/oncotarget.20467

Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties. / Dasgupta, Atreyi; Trucco, Matteo; Rainusso, Nino; Bernardi, Ronald J.; Shuck, Ryan; Kurenbekova, Lyazat; Loeb, David M.; Yustein, Jason T.

In: Oncotarget, Vol. 8, No. 44, 01.01.2017, p. 77292-77308.

Research output: Contribution to journalArticle

Dasgupta, A, Trucco, M, Rainusso, N, Bernardi, RJ, Shuck, R, Kurenbekova, L, Loeb, DM & Yustein, JT 2017, 'Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties', Oncotarget, vol. 8, no. 44, pp. 77292-77308. https://doi.org/10.18632/oncotarget.20467
Dasgupta A, Trucco M, Rainusso N, Bernardi RJ, Shuck R, Kurenbekova L et al. Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties. Oncotarget. 2017 Jan 1;8(44):77292-77308. https://doi.org/10.18632/oncotarget.20467
Dasgupta, Atreyi ; Trucco, Matteo ; Rainusso, Nino ; Bernardi, Ronald J. ; Shuck, Ryan ; Kurenbekova, Lyazat ; Loeb, David M. ; Yustein, Jason T. / Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties. In: Oncotarget. 2017 ; Vol. 8, No. 44. pp. 77292-77308.
@article{5d5eca64f4784fd5bf46af1a1076ce4c,
title = "Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties",
abstract = "Ewing sarcoma (EWS) is a highly aggressive and metabolically active malignant tumor. Metabolic activity can broadly be characterized by features of glycolytic activity and oxidative phosphorylation. We have further characterized metabolic features of EWS cells to identify potential therapeutic targets. EWS cells had significantly more glycolytic activity compared to their non-malignant counterparts. Thus, metabolic inhibitors of glycolysis such as 2-deoxy-D-glucose (2DG) and of the mitochondrial respiratory pathway, such as metformin, were evaluated as potential therapeutic agents against a panel of EWS cell lines in vitro. Results indicate that 2DG alone or in combination with metformin was effective at inducing cell death in EWS cell lines. The predominant mechanism of cell death appears to be through stimulating apoptosis leading into necrosis with concomitant activation of AMPK-α. Furthermore, we demonstrate that the use of metabolic modulators can target putative EWS stem cells, both in vitro and in vivo, and potentially overcome chemotherapeutic resistance in EWS. Based on these data, clinical strategies using drugs targeting tumor cell metabolism present a viable therapeutic modality against EWS.",
keywords = "2DG, Cancer stem cells, Ewing sarcoma, Metabolism, Metformin",
author = "Atreyi Dasgupta and Matteo Trucco and Nino Rainusso and Bernardi, {Ronald J.} and Ryan Shuck and Lyazat Kurenbekova and Loeb, {David M.} and Yustein, {Jason T.}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.20467",
language = "English (US)",
volume = "8",
pages = "77292--77308",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "44",

}

TY - JOUR

T1 - Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties

AU - Dasgupta, Atreyi

AU - Trucco, Matteo

AU - Rainusso, Nino

AU - Bernardi, Ronald J.

AU - Shuck, Ryan

AU - Kurenbekova, Lyazat

AU - Loeb, David M.

AU - Yustein, Jason T.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Ewing sarcoma (EWS) is a highly aggressive and metabolically active malignant tumor. Metabolic activity can broadly be characterized by features of glycolytic activity and oxidative phosphorylation. We have further characterized metabolic features of EWS cells to identify potential therapeutic targets. EWS cells had significantly more glycolytic activity compared to their non-malignant counterparts. Thus, metabolic inhibitors of glycolysis such as 2-deoxy-D-glucose (2DG) and of the mitochondrial respiratory pathway, such as metformin, were evaluated as potential therapeutic agents against a panel of EWS cell lines in vitro. Results indicate that 2DG alone or in combination with metformin was effective at inducing cell death in EWS cell lines. The predominant mechanism of cell death appears to be through stimulating apoptosis leading into necrosis with concomitant activation of AMPK-α. Furthermore, we demonstrate that the use of metabolic modulators can target putative EWS stem cells, both in vitro and in vivo, and potentially overcome chemotherapeutic resistance in EWS. Based on these data, clinical strategies using drugs targeting tumor cell metabolism present a viable therapeutic modality against EWS.

AB - Ewing sarcoma (EWS) is a highly aggressive and metabolically active malignant tumor. Metabolic activity can broadly be characterized by features of glycolytic activity and oxidative phosphorylation. We have further characterized metabolic features of EWS cells to identify potential therapeutic targets. EWS cells had significantly more glycolytic activity compared to their non-malignant counterparts. Thus, metabolic inhibitors of glycolysis such as 2-deoxy-D-glucose (2DG) and of the mitochondrial respiratory pathway, such as metformin, were evaluated as potential therapeutic agents against a panel of EWS cell lines in vitro. Results indicate that 2DG alone or in combination with metformin was effective at inducing cell death in EWS cell lines. The predominant mechanism of cell death appears to be through stimulating apoptosis leading into necrosis with concomitant activation of AMPK-α. Furthermore, we demonstrate that the use of metabolic modulators can target putative EWS stem cells, both in vitro and in vivo, and potentially overcome chemotherapeutic resistance in EWS. Based on these data, clinical strategies using drugs targeting tumor cell metabolism present a viable therapeutic modality against EWS.

KW - 2DG

KW - Cancer stem cells

KW - Ewing sarcoma

KW - Metabolism

KW - Metformin

UR - http://www.scopus.com/inward/record.url?scp=85030310665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030310665&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20467

DO - 10.18632/oncotarget.20467

M3 - Article

VL - 8

SP - 77292

EP - 77308

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 44

ER -